Phacilitate’s Portfolio Director Michael Adeniya shares insights from his call with Dark Horse’s CEO Anthony Davies as he encourages the industry to continue innovating and adapting. Click here for Michael’s message.…

By Nathan Manley & Katy Spink

The cell therapy field is currently in an exciting era of expansion, with a large number of candidate therapies advancing into clinical testing and many more progressing through preclinical pipelines. As the number of …

by Gareth Macdonald

The cell therapy sector faces a cost of goods sold (COGS) crisis and needs to get beyond the “product is the process” mind-set says Anthony Davies, CEO of Dark Horse Consulting.

Cell and gene therapies have attracted …

by Dan Stanton

Fully closed and automated platforms are key to reducing the current high costs of cell and gene therapy manufacturing, say industry experts.

Cell and gene therapies (CGTs) have come a long way over the past two years, …

by Dan Stanton

This is the first time in history that we can make more effective medicines than we can afford, says Dark Horse Consulting.

The Phacilitate conference took place in Miami this week, and in the plenary session Anthony …

by Dan Stanton

The US FDA predicts it will receive more than 200 regenerative INDs per year from 2020 and will add 50 additional staff to review these products.

There has been “a large upswing in the number of investigational …

by Katy Spink & Andrew Steinsapir

With the 2017 FDA approvals and launches of the first gene-modified cell and pure-play gene therapy products to gain licensure in the United States, increasing attention has been paid to the high cost of …

With extensive industry expertise, Dark Horse Consulting provides strategic and technical services to help clients realize their goals of bringing therapies to patients and commercialization as featured in Biopharma Dealmakers.

An in depth analysis and recommendations for the recently revised cell & gene therapy guidances from our founder and CEO, Anthony Davies, was featured in an editorial for Cell & Gene Therapy Insights.

Experts from North American and European organisations are also supporting the trade mission. Anthony Davies, Ph.D., CEO of Dark Horse Consulting added, “As the first and only global consulting practice focused on CMC for cell and gene therapy, Dark Horse …

Product approvals and a regulatory focus on regenerative medicines has made 2017 a breakthrough year for cell and gene therapies, say consultants.